Clinical Trial Update: Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia [NA]

View source ↗

Summary

Clinical trial evaluating intravitreal pegaptanib for myopic choroidal neovascularization has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myopic Choroidal Neovascularization

Drugs mentioned

• Macugen (pegaptanib sodium)

Snippet

Sponsor: L.V. Prasad Eye Institute | Conditions: Myopic Choroidal Neovascular Membrane | NA | Status: WITHDRAWN